Category: Moms

Autophagy and autophagy enhancers

Autophagy and autophagy enhancers

Finally, Autophgay results were obtained Functional movement screening P-type ATPase ATP13A2 in the frontal cortex of PD and DLB patients, Autophagy and autophagy enhancers Ajtophagy both decreased [ 63 ] and increased [ 64 ] protein levels have been reported compared to controls. Lee: K2A2A; H. Tumorigenesis begins with an oncogene mutation in the epithelial cell that makes the cell more likely to divide.

Autophagy and autophagy enhancers -

One of these, sequestosome 1 SQSTM1 , encodes the scaffold protein p62; both point mutations and deletions have been identified in ALS cases 50 , p62 acts as an adaptor to bind ubiquitinated targets to autophagosome-associated lipidated microtubule—associated light chain 3 LC3-II for engulfment by autophagosomes While this suggests a clear link between autophagy and ALS, p62 mutations are located throughout the protein, across multiple domains 51 , and their effect on autophagy has yet to be fully established.

This is also true for ALS-causing mutations in another adaptor, optineurin Optineurin has established roles in xenophagy, a form of autophagy that degrades foreign pathogens Optineurin can also bind to protein aggregates 56 and is sequestered in inclusions in ALS patients as well as in other neurodegenerative diseases 57 , The most common known mutation in ALS is an intronic hexanucleotide repeat expansion in the gene C9ORF Very little is known about the function of the C9ORF72 protein, and it is currently unclear whether the disease resulting from this mutation is due to a loss of function, gain of function, or both.

siRNA knockdown of C9ORF72 increased LC3-II levels, although the study did not fully characterize the meaning of this in terms of autophagy function Yet another ALS-causing gene with a clear function in autophagy is dynactin 1 DCTN1 Autophagosomes are formed throughout neurons, and their efficient movement to lysosome-rich areas for fusion and cargo degradation is dependent on dynein-mediated transport 61 , A reduction in this transport can result in impaired autophagosome-lysosome fusion, as shown by autophagosome accumulation with enhanced toxicity in cell, Drosophila , and mouse models 63 , More recently, mutations in DCTN1 have been shown to cause Perry syndrome, a neurodegenerative disease that can present with Parkinsonism and psychiatric changes 65 , suggesting a role for autophagic dysfunction in this disease.

HD is caused by polyglutamine repeat expansions in the huntingtin htt protein A role for autophagy in HD was first suggested by observations of increased levels of autophagic markers in the brains or tissues of HD patients and in mouse models of the disease 67 — In HD mouse models, the key autophagic regulator, mTOR, is sequestered into htt aggregates, resulting in an inhibition of signaling, consistent with autophagy induction While this would appear to suggest an upregulation of autophagy in HD, the situation may in fact be more complicated.

The positive autophagy regulator, beclin 1, has also been shown to be sequestered into htt aggregates 71 , which would negatively affect autophagosome formation. Moreover, the accumulated autophagosomes observed may not be fully functional; they have been shown to be relatively empty due to inefficient sequestration of cargo, in particular organelles such as mitochondria and lipid droplets, and the increase in autophagosome number is not associated with an increase in protein degradation In addition, htt itself may control autophagy through a variety of different mechanisms.

Two htt-interacting proteins, Rab5 and Rhes, are positive regulators of autophagy 73 , 74 , and htt lacking the polyglutamine repeat region induces autophagy and is protective against toxicity of mutant polyglutamine—expanded htt in cells and mice 75 , suggesting a more direct role for htt in autophagy.

While it is not yet clear whether alterations in autophagy are primary factors in the pathogenesis of HD, polymorphisms in the core autophagy gene, ATG7 , have been suggested to be associated with earlier age of onset Hereditary spastic paraplegia.

Hereditary spastic paraplegias HSPs include a broad group of neurodegenerative diseases involving degeneration associated with the lower extremities.

Two forms of HSP have been associated with mutations in genes with a role in autophagy. The first identified was TECPR2 , a positive autophagy regulator that interacts with LC3 77 , The exact function of this protein is unknown; however, it bears homology to TECPR1, which has been implicated in sequestration of bacteria into autophagosomes, suggesting a role as an autophagy adaptor Type 15 HSP is caused by mutations in ZFYVE26 79 encoding spastizin also known as FYVE-CENT , which interacts with the core autophagy protein, beclin 1.

Disease-associated mutations in spastizin compromise this interaction, leading to impaired autophagy Lafora disease. Lafora disease is an autosomal recessive myoclonous epilepsy resulting in early death due to neurodegeneration.

Its pathologic hallmark is the accumulation of Lafora bodies LBs , comprising abnormally hyperphosphorylated polyglucosan with a smaller polyubiquitinated protein component.

Most mutations in Lafora disease occur in two proteins, laforin and malin, which form a complex that, when disrupted, drives the disease reviewed in ref. LB accumulation may be partly the result of altered carbohydrate metabolism However, data from patient and animal models clearly support a role for disrupted autophagy in disease onset and progression.

Overexpression of laforin induces autophagy, while a reduction in laforin levels has the opposite effect Both laforin- and malin-deficient mice show an early defect in autophagosome biogenesis, which may lead to LB formation 83 — Both mouse models show reduced levels of autophagosomes and a reduction in total and autophagy-dependent protein degradation.

Neurodegenerative disorders associated with mutations in core autophagy genes. The likelihood that autophagy defects contribute to neurodegeneration is supported by recent studies that reveal a class of diseases caused by mutations in core autophagy genes.

Neurodegeneration with brain iron accumulation 5 NBIA5; OMIM identifier is a neurodegenerative disease that presents with movement disorder and intellectual decline. It is currently described as β-propeller protein—associated neurodegeneration BPAN or static encephalopathy of childhood with neurodegeneration in adulthood SENDA BPAN appears to be a sporadic disease, with mutations in WIPI4 occurring de novo, as parents and siblings in 20 subjects did not share the mutations In lymphoblastoid cell lines from five patients, reduced autophagic activity and an accumulation of aberrant ATG9A and LC3-II positive autophagic structures were reported This may be a direct result of disrupted ATG9A vesicle translocation at the autophagosome formation site 88 due to altered WIPI4 activity in autophagosome formation 89 , Another disease caused by an autophagy gene defect is Vici syndrome OMIM identifier , a multisystem disorder associated with callosal agenesis.

This disorder is caused by recessive mutations in EPG5 , an autophagy gene identified first in Caenorhabditis elegans Epg5 -null mice develop ALS-like features The evidence outlined above suggests a possible role for autophagic dysfunction in the pathogenesis of neurodegenerative diseases, but autophagy also has the ability to decrease the accumulation of toxic, aggregate-prone proteins that cause neurodegeneration.

These aggregate-prone proteins are frequently substrates for both the ubiquitin-proteasome system and autophagy as monomers. However, because the oligomeric forms of these proteins cannot pass through the narrow entrance of the proteasome, such higher-order species may be targeted to autophagy.

While the appearance of intracytoplasmic inclusions is reduced by autophagy upregulation, our working model is that autophagy does not clear the large aggregates directly, but rather clears the soluble aggregate precursors, shifting the equilibrium from aggregate formation toward degradation Multiple studies provide proof of principle for the modulation of autophagy as a therapy for neurodegenerative disease.

In vitro work examining the effect of autophagy upregulation on the clearance of a wide range of aggregation-prone proteins including those with polyQ and polyA expansions 5 , 8 , mutant tau and ataxin-3 8 , and mutant α-synuclein 6 , 94 has suggested reductions in both intracytoplasmic aggregates and associated cell death.

Additionally, autophagy also protects against both proapoptotic 95 , 96 and pro-necrotic 97 insults, which may contribute to its benefits. The protective effect seen from autophagy induction in cell models has been successfully translated into a range of animal models, in Drosophila melanogaster models of both tauopathies 8 and HD 70 , 98 , and also in mammalian models of disease, including HD, spinocerebellar ataxia type III, tauopathy, PD, and even familial prion disease see Table 1 for studies of autophagy upregulation in mouse models of neurodegeneration.

Together these studies demonstrate that autophagy upregulation and promotion of aggregation-prone protein degradation ameliorate neurodegenerative pathology. Therapeutic upregulation of autophagy in transgenic mouse models of neurodegenerative disease. It is important to note that autophagy inducers are unlikely to be panaceas for all neurodegenerative diseases.

Indeed, in diseases associated with impaired autophagosome clearance e. A greater understanding of the potential mechanisms of autophagic dysfunction in neurodegenerative disease as outlined in the first part of this Review is therefore vital for development of therapeutics.

The autophagy-modulating agents used in preclinical trials in models of neurodegenerative disease have diverse mechanisms of action. Our understanding of how many of these agents work is not complete; however, they can be divided into mTOR-dependent and mTOR-independent agents.

mTOR-dependent pharmacologic agents. mTOR is found in two different functional complexes. mTOR complex 1 mTORC1 is a negative autophagy regulator, and mTORC2 is a positive regulator The allosteric mTORC1 inhibitor rapamycin was the first drug to be identified as an autophagy inducer , Rapamycin forms a complex with FKbinding protein 12 FKBP12 , which binds to and inhibits the kinase activity of mTORC1 , Although the mTOR pathway is involved in a wide range of cellular functions reviewed in ref.

The limited absorption of rapamycin has driven the development of many so-called rapalogs such as temsirolimus CCI , everolimus RAD , and ridaforolimus AP To date, it is these rapalogs that have been investigated most widely in terms of their potential therapeutic value in neurodegenerative diseases.

Newly developed mTOR inhibitors include the ATP-competitive mTOR inhibitors reviewed in ref. These results indicate the broad spectrum of biological activities of lithium and valproic acid, as suggest that a complex network of processes is involved in the pathogenesis of HD.

Valproic acid inhibits activity of myo-inositolphosphate synthase, one of enzymes involved in the metabolism of inositol Shaltiel et al. Combination of valproic acid and lithium was tested in clinical trials with HD patients. However, in most cases either a lack of effects or only stabilization of symptoms with no improvement were observed Scheuing et al.

AD model cells were treated with valproic acid, and no changes with the total amount of beta-amyloid were demonstrated while level of beta-amyloid oligomers which are suggested to be more toxic decreased and level of monomers increased, relative to untreated control cells Williams and Bate This may suggest that beta-amyloid oligomers are converted to monomers in valproic acid-treated cells.

Streptozotocin STZ -induced rat model of AD has been used in in vivo studies. Intraventricular injection of STZ provokes neurodegeneration and accumulation of beta-amyloid and hyperphosphorylated tau protein, thus, mimicking the sporadic form of AD. Decreased levels of acetylcholine and neprylysine, and increased activity of acetylcholinesterase cause additionally enhanced neurodegeneration and cognitive defects.

Treatment with valproic acid resulted in prevention of cognitive deficits and normalization of levels and activities of neurotransmitters Sorial and El Sayed Using another animal model of AD, transgenic mice expressing a mutated APP gene, effects of valproic acid in males and females were compared.

Decreased levels of amyloid plaques were more pronounced in males than in females, while number of synaptic vesicles were similar in both genders. On the other hand, neurodegeneration was prevented more efficiently in males Long et al.

Cellular models of PD were used to investigate the mechanism of action of valproic acid. This compound caused reduction of levels of proapoptotic proteins and ROS, while autophagy inhibitors diminished these effects, indicating a crucial role of this process in valproic acid-mediated improvement in PD cellular phenotypes Zhang et al.

Other in vitro studies were based on the use of murine neurons treated with human beta-amyloid. Defects in synaptic proteins and neurotransmitter transporting vesicles were observed. These effects were alleviated by addition of valproic acid into the cell culture. A mechanism has been proposed in which this compound negatively regulates cytoplasmic phospholipase A2 cPLAS2 , whose overactivity correlates with neurodegeneration.

Autophagy has been suggested as an additional mechanism of the observed changes in cells Williams and Bate Controversial results were obtained in studies on prion disease. Early studies suggested that valproic acid causes an increased accumulation of PrP in neuroblastoma cells and model cells for the disease.

However, administration of valproic acid to Chinese hamsters infected with prions did not cause any effects on the course of the disease Shaked et al. Other studies performed with cellular models did not confirm effects of valproic acid on the levels of PrP Legendre et al. Mechanism of action of carbamazepine is similar to that by valproic acid and lithium Williams et al.

A decrease in the inositol level arises from deprivation of PIP2 and IP3 Schiebler et al. Studies with the mouse model of AD indicated that carbamazepine improved learning abilities and memory, which was correlated with decreased number of amyloid plaques Li et al.

Apart from stimulation of mTOR-independent pathway of autophagy activation, carbamazepine inhibited the mTOR kinase activity. Therefore, it is another example of autophagy stimulation by more than one molecular mechanism Li et al. Since carbamazepine is known as an analgesic, anticonvulsant and antiepileptic drug, it has been used for treatment of HD patients Danivas et al.

It was proposed that its mechanisms of action is related to blocking calcium channels which cause inhibition of glutamate liberation Kawata et al. Intriguingly, autophagy was not considered as a mechanism by which carbamazepine improves symptoms of HD.

An interesting case report has been published in which carbamazepine was administered to a patient suffering from hypertension, myocardial infraction, and atrial fibrillation.

When high doses of the drug were used as the patient became resistant to lower doses , many adverse effects were noted, including memory deficits, confusion, psychomotor slowness, hypersomnia, dysphasia, and postural instability with falls.

Psychological tests indicated attentional deficits, perseverations, severe non-fluent aphasia with paraphasias, and constructional apraxia. The EEG results were similar to those found in patients suffering from Creutzfeldt—Jakob disease.

Cognitive deficit and motor dysfunctions normalized. Thus, it was concluded that carbamazepine caused Creutzfeldt—Jakob disease-like symptoms Horvath et al. Clonidine binds and activates the imidazoline receptor, which leads to a decrease in the level of cAMP in cells Williams et al.

However, it appears that there is an additional mechanism of action of this compound, namely activation of potassium channels which causes a decrease in concentration of calcium ions in the cytoplasm Murphy and Freedman Clonidine was used as one of compounds activating autophagy in the screening for a potential drug for HD and PD.

It was effective in reducing amounts of synuclein and mHTT in cells Williams et al. In vivo experiments were performed with reserpine-treated rat model of Parkinson's disease.

Following injection of reserpine, severe akinesis was observed which could be prevented by previous treatment with clonidine Hill and Brotchie However, stimulation of autophagy was not considered as a potential mechanism of action of this drug.

In PD potential therapies concentrate on inhibition of movements while patients suffer also from cognitive deficits and mood swings. When clonidine, as an agonist of adrenergic receptor alpha-2, was tested as a potential drug at early phase of PD in a monkey model Macaca fasicularis , it was found that the treatment caused improvement in concentration and memory Schneider et al.

Models of memory deficits were also used in studies on clonidine. In murine models, the symptoms were induced by administration of NMDA N-methyl-D-aspartate antagonist MK or by excitotoxic hippocampal damage. Clonidine ameliorated symptoms caused by MK, but did not change behavior of rats in which hippocampus was damaged by excitotoxic agents Bardgett et al.

The only studies on the use of clonidine in prion disease were performed with the yeast model. However, no significant effects on the level of PrPSC could be observed Tribouillard-Tanvier et al. Similarly to clonidine, it binds and activates the imidazoline receptor.

It was tested in experiments with cellular HD and PD models, and caused a decrease in levels of mHTT and alpha-synuclein Williams et al. In the mouse model of HD, reduction of mHTT levels was also observed but number of aggregates remained unchanged.

Although rilmenidine could not prevent the body weight loss, it corrected the muscle parameters and general condition of the organism Rose et al.

Although a clinical study with 18 HD patients has been conducted, only 12 patients completed this trial. Some cognitive parameters and motor functions were improved Underwood et al.

Cellular and animal models of ALS were used to study effects of rilmenidine in this disease. A decrease in mutant SOD1 level was observed in cells in which macroautophagy and mitophagy were also evident.

Similarly, administration of this drug to mice suffering from ALS resulted in autophagy induction in motor neurons. Unexpectedly, enhanced degeneration of these neurons was observed under these conditions.

Moreover, accumulation of SOD aggregates and a decrease in number of mitochondria occurred in treated animals, and correlated with more severe symptoms relative to untreated mice.

It was suggested that too extensive mitophagy could be responsible for these effects Perera et al. No reports were published on the use of this compound in experiments with animal models. When cellular model of AD was employed, treatment with SMER28 prevented formation of beta-amyloid aggregates in a dose-response mode Shen et al.

When production of Beclin-1 was impaired, effects of SMER28 were diminished. Similar effects were observed in experiments with silencing of expression of the gene coding for ULK kinase. Therefore, SMER28 appears to stimulate mTOR-dependent and mTOR-independent mechanisms of autophagy activation pathways Tian et al.

There are various possibilities to induce autophagy. In this review, mechanisms of these pathways were discussed to indicate how this process can be stimulated, which is in contrast to most other review article that described mechanisms of negative regulations in fact autophagy is regulated by various inhibitors.

Stimulation of autophagy has been considered as a strategy for treatment of various neurodegenerative diseases.

Although there are many encouraging results obtained in experiments with cellular and animal models described in this review in particular sections presenting various ways of autophagy stimulation , specific treatments of metabolic brain diseases are not yet available.

One of the most important problem is appearance of severe adverse effects when strong autophagy stimulators are tested. Such effects were observed for rapamycin, nimodipine, loperamide, niguldipine, nicardipine, panitrem A, fluspirilene, calpastatin, and carbamazepine.

Therefore, a compound which activates this process but is also safe in the long-term use is highly desirable.

In this light it is worth mentioning that genistein 5, 7-dihydroxy 4-hydroxyphenyl -4 H benzopyranone , a natural isoflavone, has been demonstrated recently to decrease levels of mutant huntingtin and to reduce number and size of aggregates of this toxic protein in the cellular model of HD by autophagy stimulation Pierzynowska et al.

This isoflavone could alleviate lysosomal storage of glycosaminoglycans in vitro and in vivo in visceral organs and in the brain , and correct animal behavior in various models of mucopolysaccharidosis type I, II and III, a neurodegenerative metabolic disease Piotrowska et al.

Therefore, it may be considered as a promising agent for development of an effective and safe therapeutics for treatment of neurodegenerative diseases by stimulation of autophagy. Interestingly, one compound is sometimes able to activate the autophagy process by both mTOR-dependent and mTOR-independent pathways.

Such molecules exemplified by L-NG-nitroarginine methyl ester, trehalose, pimozide or trifluoperazine are often very effective in removing toxic protein aggregates from cells. It is worth noting that there are links between different mTOR-dependent pathways, which may enhance effects of certain activators of autophagy.

Although no such links were discovered between mTOR-dependent and mTOR-independent pathways, the existence of compounds that stimulate autophagy by both these mechanisms might suggest a possibility that there are some cross-talks between molecules involved in both types of pathways.

Marianne O. Klein, Daniella S. Battagello, … Ricardo G. Ballard C, Lana MM, Theodoulou M, Douglas S, McShane R, Jacoby R, Kossakowski K, Yu LM, Juszczak E, Investigators DARTAD A randomised, blinded, placebo-controlled trial in dementia patients continuing or stopping neuroleptics the DART-AD trial.

PLoS Med 5:e Article PubMed PubMed Central CAS Google Scholar. Ballard C, Hanney ML, Theodoulou M, Douglas S, McShane R, Kossakowski K, Gill R, Juszczak E, Yu LM, Jacoby R, investigators DART-AD The dementia antipsychotic withdrawal trial DART-AD : long-term follow-up of a randomised placebo-controlled trial.

Lancet Neurol — Article PubMed CAS Google Scholar. Bardgett ME, Points M, Ramsey-Faulkner C, Topmiller J, Roflow J, McDaniel T, Lamontagne T, Griffith MS The effects of clonidine on discrete-trial delayed spatial alternation in two rat models of memory loss.

Neuropsychopharmacology — Berger Z, Ravikumar B, Menzies FM, Oroz LG, Underwood BR, Pangalos MN, Schmitt I, Wullner U, Evert BO, O'Kane CJ, Rubinsztein DC Rapamycin alleviates toxicity of different aggregate-prone proteins. Hum Mol Genet Article CAS Google Scholar.

Berridge MJ Inositol trisphosphate and calcium signalling. Nature — Berridge MJ, Bootman MD, Roderick HL Calcium signalling: dynamics, homeostasis and remodelling. Nat Rev Mol Cell Biol — Bharadwaj PR, Bates KA, Porter T, Teimouri E, Perry G, Steele JW, Gandy S, Groth D, Martins RN, Verdile G Latrepirdine: molecular mechanisms underlying potential therapeutic roles in Alzheimer's and other neurodegenerative diseases.

Transl Psychiatry 3:e Cell Signal — Burkewitz K, Zhang Y, Mair WB AMPK at the nexus of energetics and aging. Cell Metab — Caccamo A, Majumder S, Richardson A, Strong R, Oddo S Molecular interplay between mammalian target of rapamycin mTOR , amyloid-beta, and Tau: effects on cognitive impairments.

J Biol Chem — Carew JS, Medina EC, Esquivel JA II, Mahalingam D, Swords R, Kelly K, Zhang H, Huang P, Mita AC, Mita MM, Giles FJ, Nawrocki ST Autophagy inhibition enhances vorinostat-induced apoptosis via ubiquitinated protein accumulation.

J Cell Mol Med — Article PubMed Central CAS Google Scholar. Castillo K, Nassif M, Valenzuela V, Rojas F, Matus S, Mercado G, Court FA, van Zundert B, Hetz C Trehalose delays the progression of amyotrophic lateral sclerosis by enhancing autophagy in motoneurons.

Autophagy — Chau S, Herrmann N, Ruthirakuhan MT, Chen JJ, Lanctôt KL Latrepirdine for Alzheimer's disease. Cochrane Database Syst Rev 4:CD Article Google Scholar.

Cortes CJ, Qin K, Cook J, Solanki A, Mastrianni JA Rapamycin delays disease onset and prevents PrP plaque deposition in a mouse model of Gerstmann-Sträussler-Scheinker disease.

J Neurosci — Cuervo AM Autophagy: many paths to the same end. Mol Cell Biochem — Danivas V, Moily NS, Thimmaiah R, Muralidharan K, Purushotham M, Muthane U, Jain S Off label use of lithium in the treatment of Huntington's disease: A case series.

Indian J Psychiatry — Article PubMed PubMed Central Google Scholar. DeBosch BJ, Heitmeier MR, Mayer AL, Higgins CB, Crowley JR, Kraft TE, Chi M, Newberry EP, Chen Z, Finck BN, Davidson NO, Yarasheski KE, Hruz PW, Moley KH Trehalose inhibits solute carrier 2A SLC2A proteins to induce autophagy and prevent hepatic steatosis.

Sci Signal 9:ra Diepenbroek M, Casadei N, Esmer H, Saido TC, Takano J, Kahle PJ, Nixon RA, Rao MV, Melki R, Pieri L, Helling S, Marcus K, Krueger R, Masliah E, Riess O, Nuber S Overexpression of the calpain-specific inhibitor calpastatin reduces human alpha-Synuclein processing, aggregation and synaptic impairment in [A30P] αSyn transgenic mice.

Hum Mol Genet — Dong H, Czaja MJ Regulation of lipid droplets by autophagy. Trends Endocrinol Metab — Fimia GM, Stoykova A, Romagnoli A, Giunta L, Di Bartolomeo S, Nardacci R, Corazzari M, Fuoco C, Ucar A, Schwartz P, Gruss P, Piacentini M, Chowdhury K, Cecconi F Ambra1 regulates autophagy and development of nervous system.

Friso A, Tomanin R, Salvalaio M, Scarpa M Genistein reduces glycosaminoglycan levels in a mouse model of mucopolysaccharidosis type II. Br J Pharmacol — Gaballah HH, Zakaria SS, Elbatsh MM, Tahoon NM Modulatory effects of resveratrol on endoplasmic reticulum stress-associated apoptosis and oxido-inflammatory markers in a rat model of rotenone-induced Parkinson's disease.

Chem Biol Interact — Ganley IG, Wong PM, Gammoh N, Jiang X Distinct autophagosomal—lysosomal fusion mechanism revealed by thapsigargin-induced autophagy arrest. Mol Cell — Gautam S, Karmakar S, Batra R, Sharma P, Pradhan P, Singh J, Kundu B, Chowdhury PK Polyphenols in combination with β-cyclodextrin can inhibit and disaggregate α-synuclein amyloids under cell mimicking conditions: A promising therapeutic alternative.

Biochim Biophys Acta — Girotti F, Carella F, Scigliano G, Grassi MP, Soliveri P, Giovannini P, Parati E, Caraceni T Effect of neuroleptic treatment on involuntary movements and motor performances in Huntington's disease.

J Neurol Neurosurg Psychiatry — Glick D, Barth S, Macleod KF Autophagy: cellular and molecular mechanism. J Pathol — Gloerich M, Bos JL Epac: defining a new mechanism for cAMP action. Annu Rev Pharmacol Toxicol — Goll DE, Thompson VF, Li H, Wei W, Cong J The calpain system.

Physiol Rev — Gordon PB, Holen I, Fosse M, Røtnes JS, Seglen PO Dependence of hepatocytic autophagy on intracellularly sequestered calcium.

PubMed CAS Google Scholar. Guo YJ, Dong SY, Cui XX, Feng Y, Liu T, Yin M, Kuo SH, Tan EK, Zhao WJ, Wu YC Resveratrol alleviates MPTP-induced motor impairments and pathological changes by autophagic degradation of α-synuclein via SIRT1-deacetylated LC3.

Mol Nutr Food Res — Article PubMed CAS PubMed Central Google Scholar. Gutierrez MG, Munafó DB, Berón W, Colombo MI Rab7 is required for the normal progression of the autophagic pathway in mammalian cells. J Cell Sci — Hara T, Takamura A, Kishi C, Iemura S, Natsume T, Guan JL, Mizushima N FIP, a ULK1 interacting protein, is required for autophagosome formation in mammalian cells.

J Cell Biol — Hayashi-Nishino M, Fujita N, Noda T, Yamaguchi A, Yoshimori T, Yamamoto A A subdomain of the endoplasmic reticulum forms a cradle for autophagosome formation. Nat Cell Biol — Article PubMed Google Scholar. Hill MP, Brotchie JM The adrenergic receptor agonist, clonidine, potentiates the anti-parkinsonian action of the selective κ-opioid receptor agonist, enadoline, in the monoamine-depleted rat.

Ho DJ, Calingasan NY, Wille E, Dumont M, Beal MF Resveratrol protects against peripheral deficits in a mouse model of Huntington's disease. Exp Neurol — Höllerhage M, Goebel JN, de Andrade A, Hildebrandt T, Dolga A, Culmsee C, Oertel WH, Hengerer B, Höglinger GU Trifluoperazine rescues human dopaminergic cells from wild-type α-synuclein-induced toxicity.

Neurobiol Aging — Horvath J, Coeytaux A, Jallon P, Landis T, Temperli P, Burkhard PR Carbamazepine encephalopathy masquerading as Creutzfeldt-Jakob disease. Neurology — Hosokawa N, Sasaki T, Iemura SI, Natsume T, Hara T, Mizushima N a Atg, a novel mammalian autophagy protein interacting with Atg Hosokawa N, Hara T, Kaizuka T, Kishi C, Takamura A, Miura Y, Iemura S, Natsume T, Takehana K, Yamada N, Guan JL, Oshiro N, Mizushima N b Nutrient-dependent mTORC1 association with the ULK1—Atg13—FIP complex required for autophagy.

Mol Biol Cell — Høyer-Hansen M, Jäättelä M AMP-activated protein kinase: a universal regulator of autophagy? Huang J, Manning BD The TSC1-TSC2 complex: a molecular switchboard controlling cell growth.

Biochem J — Inoki K, Zhu T, Guan KL TSC2 mediates cellular energy response to control cell growth and survival. Cell — Inoki K, Ouyang H, Zhu T, Lindvall C, Wang Y, Zhang X, Yang Q, Bennett C, Harada Y, Stankunas K et al TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth.

Jacinto E, Loewith R, Schmidt A, Lin S, Rüegg MA, Hall A, Hall MN Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive.

Jung CH, Ro SH, Chao J, Otto NM, Kim DH mTOR regulation of autophagy. FEBS Lett — Kalonia H, Kumar P, Kumar A Attenuation of proinflammatory cytokines and apoptotic process by verapamil and diltiazem against quinolinic acid induced Huntington like alterations in rats.

Brain Res — Kaushik S, Bandyopadhyay U, Sridhar S, Kiffin R, Martinez-Vicente M, Kon M, Orenstein SJ, Wong E, Cuervo AM Chaperon-mediated autophagy at a glance. Kim R Recent advances in understanding the cell death pathways activated by anticancer therapy.

Cancer — Kim J, Kim E Rag GTPase in amino acid signaling. Amino Acids — Kim DH, Sarbassov DD, Ali SM, King JE, Latek RR, Erdjument-Bromage H, Tempst P, Sabatini DM mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery.

Kim KH, Dodsworth C, Paras A, Burton BK High dose genistein aglycone therapy is safe in patients with mucopolysaccharidoses involving the central nervous system. Mol Genet Metab — Kim YD, Jeong EI, Nah J, Yoo SM, Lee WJ, Kim Y, Moon S, Hong SH, Jung YK Pimozide reduces toxic forms of tau in TauC3 mice via 5' adenosine monophosphate-activated protein kinase-mediated autophagy.

J Neurochem — Klionsky DJ The molecular machinery of autophagy: unanswered questions. Köchl R, Hu XW, Chan EY, Tooze SA Microtubules facilitate autophagosome formation and fusion of autophagosomes with endosomes.

Traffic — Kondo Y, Kanzawa T, Sawaya R, Kondo S The role of autophagy in cancer development and response to therapy. Nat Rev Cancer — Kost A, Kasprowska D, Łabuzek K, Wiaderkiewicz R, Gabryel B Autofagia w niedokrwieniu mózgu.

Postepy Hig Med Dosw — Krüger U, Wang Y, Kumar S, Mandelkow EM Autophagic degradation of tau in primary neurons and its enhancement by trehalose. Kuma A, Hatano M, Matsui M, Yamamoto A, Nakaya H, Yoshimori T, Ohsumi Y, Tokuhisa T, Mizushima N The role of autophagy during the early neonatal starvation period.

Kumar P, Padi SS, Naidu PS, Kumar A Effect of resveratrol on 3-nitropropionic acid-induced biochemical and behavioural changes: possible neuroprotective mechanisms. Behav Pharmacol — Lan DM, Liu FT, Zhao J, Chen Y, Wu JJ, Ding ZT, Yue ZY, Ren HM, Jiang YP, Wang J Effect of trehalose on PC12 cells overexpressing wild-type or A53T mutant α-synuclein.

Neurochem Res — Lauterbach EC Neuroprotective effects of psychotropic drugs in Huntington's disease. Int J Mol Sci — Legendre C, Casagrande F, Andrieu T, Dormont D, Clayette P Sodium valproate does not augment Prpsc in murine neuroblastoma cells.

Neurotox Res — Lermontova NN, Lukoyanov NV, Serkova TP, Lukoyanova EA, Bachurin SO Dimebon improves learning in animals with experimental Alzheimer's disease. Bull Exp Biol Med — Li XZ, Chen XP, Zhao K, Bai LM, Zhang H, Zhou XP Therapeutic effects of valproate combined with lithium carbonate on MPTP-induced parkinsonism in mice: possible mediation through enhanced autophagy.

Int J Neurosci — Liang C, Jung JU Autophagy genes as tumor suppressors. Curr Opin Cell Biol — Linares GR, Chiu CT, Scheuing L, Leng Y, Liao HM, Maric D, Chuang DM Preconditioning mesenchymal stem cells with the mood stabilizers lithium and valproic acid enhances therapeutic efficacy in a mouse model of Huntington's disease.

Liu XW, Su Y, Zhu H, Cao J, Ding WJ, Zhao YC, He QJ, Yang B HIF-1a-dependent autophagy protects HeLa cells from fenretinide 4-HPR -induced apoptosis in hypoxia. Pharmacol Res — Acta Biochim Biophys Sin Shanghai — Majerus PW Inositol phosphate biochemistry.

Annu Rev Biochem — Majumder S, Richardson A, Strong R, Oddo S Inducing autophagy by rapamycin before, but not after, the formation of plaques and tangles ameliorates cognitive deficits.

PLoS One 6:e Malinowska M, Wilkinson FL, Bennett W, Langford-Smith KJ, O'Leary HA, Jakobkiewicz-Banecka J, Wynn R, Wraith JE, Wegrzyn G, Bigger BW Genistein reduces lysosomal storage in peripheral tissues of mucopolysaccharide IIIB mice. Malinowska M, Wilkinson FL, Langford-Smith KJ, Langford-Smith A, Brown JR, Crawford BE, Vanier MT, Grynkiewicz G, Wynn RF, Wraith JE, Wegrzyn G, Bigger BW Genistein improves neuropathology and corrects behaviour in a mouse model of neurodegenerative metabolic disease.

PLoS One 5:e Mariňo G, López-Otín C Autophagy: molecular mechanism, physiological functions and relevance in human pathology. Cell Mol Life Sci — Massacesi C, di Tomaso E, Fretault N, Hirawat S Challenges in the clinical development of PI3K inhibitors. Ann N Y Acad Sci — Mehrpour M, Esclatine A, Beau I, Codogno P Overview of macroautophagy regulation in mammalian cells.

Cell Res — Meijer AJ, Codogno P Regulation and role of autophagy in mammalian cells. Int J Biochem Cell Biol — Meijer AJ, Codogno P AMP-activated protein kinase and autophagy. Meléndez A, Tallóczy Z, Seaman M, Eskelinen EL, Hall DH, Levine B Autophagy genes are essential for dauer development and life-span extension in C.

Science — Menzies FM, Garcia-Arencibia M, Imarisio S, O'Sullivan NC, Ricketts T, Kent BA, Rao MV, Lam W, Green-Thompson ZW, Nixon RA, Saksida LM, Bussey TJ, O'Kane CJ, Rubinsztein DC Calpain inhibition mediates autophagy-dependent protection against polyglutamine toxicity.

Cell Death Differ — Mercer CA, Kaliappan A, Dennis PB A novel, human Atg13 binding protein, Atg, interacts with ULK1 and is essential for macroautophagy. Mijaljica D, Prescott M, Devenish RJ Microautophagy in mammalian cells: revisiting a year-old conundrum.

Miller RG, Shepherd R, Dao H, Khramstov A, Mendoza M, Graves J, Smith S a Controlled trial of nimodipine in amyotrophic lateral sclerosis. Neuromuscul Disord — Miller RG, Smith SA, Murphy JR, Brinkmann JR, Graves J, Mendoza M, Sands ML, Ringel SP b A clinical trial of verapamil in amyotrophic lateral sclerosis.

Muscle Nerve — Milutinović A Lithium chloride could aggravate brain injury caused by 3-nitropropionic acid. Bosn J Basic Med Sci — Mitterreiter S, Page RM, Kamp F, Hopson J, Winkler E, Ha HR, Hamid R, Herms J, Mayer TU, Nelson DJ, Steiner H, Stahl T, Zeitschel U, Rossner S, Haass C, Lichtenthaler SF Bepridil and amiodarone simultaneously target the Alzheimer's disease beta- and gamma-secretase via distinct mechanisms.

Mothi M, Sampson S Pimozide for schizophrenia or related psychoses. Cochrane Database Syst Rev CD Eur J Pharmacol R1—R3. Nakatogawa H, Suzuki K, Kamada Y, Ohsumi Y Dynamics and diversity in autophagy mechanism: lessons from yeast. Nicklin P, Bergman P, Zhang B, Triantafellow E, Wang H, Nyfeler B, Yang H, Hild M, Kung C, Wilson C et al Bidirectional transport of amino acids regulates mTOR and autophagy.

Nimmrich V, Eckert A Calcium channel blockers and dementia. Ozcelik S, Fraser G, Castets P, Schaeffer V, Skachokova Z, Breu K, Clavaguera F, Sinnreich M, Kappos L, Goedert M, Tolnay M, Winkler DT Rapamycin attenuates the progression of tau pathology in PS tau transgenic mice.

PLoS One 8:e Paris D, Bachmeier C, Patel N, Quadros A, Volmar CH, Laporte V, Ganey J, Beaulieu-Abdelahad D, Ait-Ghezala G, Crawford F, Mullan MJ Selective antihypertensive dihydropyridines lower Aβ accumulation by targeting both the production and the clearance of Aβ across the blood-brain barrier.

Mol Med — Pattingre S, Tassa A, Qu X, Garuti R, Liang XH, Mizushima N, Packer M, Schneider MD, Levine B Bcl-2 antiapoptotic proteins inhibit Beclin 1-dependent autophagy. Pattingre S, Espert L, Biard-Piechaczyk M, Codogno P Regulation of macroautophagy by mTOR and Beclin 1 complexes.

Biochimie — Perera ND, Sheean RK, Lau CL, Shin YS, Beart PM, Horne MK, Turner BJ Rilmenidine promotes MTOR-independent autophagy in the mutant SOD1 mouse model of amyotrophic lateral sclerosis without slowing disease progression. Google Scholar.

Mol Cell Neurosci — Pierzynowska K, Gaffke L, Hać A, Mantej J, Niedziałek N, Brokowska J, Węgrzyn G Correction of Huntington's disease phenotype by genistein-induced autophagy in the cellular model. NeuroMolecular Med Piotrowska E, Jakobkiewicz-Banecka J, Baranska S, Tylki-Szymanska A, Czartoryska B, Wegrzyn A, Wegrzyn G Genistein-mediated inhibition of glycosaminoglycan synthesis as a basis for gene expression-targeted isoflavone therapy for mucopolysaccharidoses.

Eur J Hum Genet — Cold Spring Harb Perspect Med 2:a Qu X, Zou Z, Sun Q, Luby-Phelps K, Cheng P, Hogan RN, Gilpin C, Levine B Autophagy gene-dependent clearance of apoptotic cells during embryonic development. Rao MV, Mohan PS, Peterhoff CM, Yang DS, Schmidt SD, Stavrides PH, Campbell J, Chen Y, Jiang Y, Paskevich PA, Cataldo AM, Haroutunian V, Nixon RA Marked calpastatin CAST depletion in Alzheimer's disease accelerates cytoskeleton disruption and neurodegeneration: neuroprotection by CAST overexpression.

Nakagawa, Y. TFE3 transcriptionally activates hepatic IRS-2, participates in insulin signaling and ameliorates diabetes. Perera, R. Transcriptional control of autophagy-lysosome function drives pancreatic cancer metabolism.

Kurz, T. Lysosomes and oxidative stress in aging and apoptosis. Acta , — Salminen, A. Regulation of the aging process by autophagy. Trends Mol. Sun, N. Measuring In vivo mitophagy. Cell 60 , — Heit, J. Jiang, L. Constitutively active calcineurin in skeletal muscle increases endurance performance and mitochondrial respiratory capacity.

Article CAS Google Scholar. Arkan, M. IKK-beta links inflammation to obesity-induced insulin resistance. Cai, D. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB.

Hirosumi, J. A central role for JNK in obesity and insulin resistance. Ozcan, U. Endoplasmic reticulum stress links obesity, insulin action, and type 2 Diabetes.

Article ADS PubMed Google Scholar. Petersen, K. Mitochondrial dysfunction in the elderly: possible role in insulin resistance. Koga, H. Altered lipid content inhibits autophagic vesicular fusion. Chang, I. Pyruvate inhibits zinc-mediated pancreatic islet cell death and diabetes.

Diabetologia 46 , — In vivo analysis of autophagy in response to nutrient starvation using transgenic mice expressing a fluorescent autophagosome marker. Hasan, M. Trex1 regulates lysosomal biogenesis and interferon-independent activation of antiviral gene. Kim, H. Toll-like receptor 2 senses beta-cell death and contributes to the initiation of autoimmune diabetes.

Immunity 27 , — Download references. The authors thank M. Jȁȁttelȁ for kind provision of p RLuc CA - LC3 WT and p RLuc CA - LC3 GA constructs and J.

Song for measurement of in vivo concentration of MSL or MSL Youle, E. Jho, A. Ballabio, L. Scorrano, T. Yoshimori, and H. Xu, respectively. M-S Lee and HJ Kwon are the recipient of UNIST Fund M3A9D to M-S Lee and NRF grants M. Lee: K2A2A; H. Kwon: K1A1A and M3A9C Severance Biomedical Science Institute, Seoul, Korea.

Department of Health Sciences and Technology, SAIHST, Sungkyunkwan University, Seoul, Korea. Department of Oral Biology, Yonsei University College of Dentistry, Seoul, Korea.

Global Research Laboratory, Department of Biotechnology, College of Life Science and Biotechnology, Yonsei University, Seoul, Korea. Department of Chemistry, Gwangju Institute of Science and Technology, Gwangju, Korea. Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.

You can also search for this author in PubMed Google Scholar. and M. conceived the study. designed the experiments. conducted the experiments. wrote the manuscript with input from other authors. Correspondence to Myung-Shik Lee.

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4. Reprints and permissions. Lim, H. A novel autophagy enhancer as a therapeutic agent against metabolic syndrome and diabetes. Nat Commun 9 , Download citation. Received : 22 March Accepted : 23 March Published : 12 April Anyone you share the following link with will be able to read this content:.

Sorry, a shareable link is not currently available for this article. Provided by the Springer Nature SharedIt content-sharing initiative. Molecular and Cellular Biochemistry By submitting a comment you agree to abide by our Terms and Community Guidelines.

If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate. Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Skip to main content Thank you for visiting nature. nature nature communications articles article. Download PDF. Subjects Macroautophagy Type 2 diabetes. Abstract Autophagy is a critical regulator of cellular homeostasis, dysregulation of which is associated with diverse diseases. Results Screening of autophagy enhancer small molecules To screen autophagy enhancers, we stably transfected HepG2 cells with wild-type WT p RLuc CA - LC3 or a mutant with GA substitution that is resistant to proteolytic cleavage and inhibits LC3-II formation [p RLuc CA - LC3 GA ] Full size image.

Discussion We here developed new potential therapeutics that can enhance autophagic activity and improve the metabolic profile of mice with metabolic syndrome and obesity. Cell death assay When treatment with chemicals was completed, medium was removed and 0.

Imaging and image quantification Imaging was conducted using an LSM confocal microscope Zeiss. Antibodies and Western blot analysis Cells or tissues were solubilized in a lysis buffer containing protease inhibitors. Mice experiments were not randomized and conducted without employing the blinding technique All animal experiments were conducted in accordance with the Public Health Service Policy in Humane Care and Use of Laboratory Animals.

NF-κB reporter assay NF-κB reporter activity was determined using pELAM-luciferase NF-κB reporter construct, as previously described Blood chemistry and hemogram Blood chemistry was determined using a Fuji Dri-Chem analyzer.

Data availability All data related to this manuscript and Supplementary Information are available from the corresponding author upon reasonable request. References Klionsky, D. Article ADS CAS PubMed PubMed Central Google Scholar Mizushima, N. Article CAS PubMed Google Scholar Kim, K.

Article CAS PubMed Google Scholar Ebato, C. Article CAS PubMed Google Scholar Jung, H. Article CAS PubMed Google Scholar Quan, W. Article CAS PubMed Google Scholar Lim, Y.

Article CAS PubMed Google Scholar Pyo, J. Article PubMed PubMed Central Google Scholar Eisenberg, T. Article CAS PubMed Google Scholar Rubinsztein, D. Article CAS PubMed PubMed Central Google Scholar Shoji-Kawata, S. Article ADS CAS PubMed PubMed Central Google Scholar Zhang, L.

Google Scholar Faskas, T. Article Google Scholar Barlow, A. Article CAS PubMed PubMed Central Google Scholar Sarbessov, D. Article Google Scholar Kimura, S. Article CAS PubMed Google Scholar Moriyama, Y. Article CAS PubMed Google Scholar Settembre, C. Article ADS CAS PubMed PubMed Central Google Scholar Shen, H.

Article CAS PubMed Google Scholar Nezich, C. Article CAS PubMed PubMed Central Google Scholar Settembre, C. Article CAS PubMed PubMed Central Google Scholar Medina, D.

Article PubMed PubMed Central Google Scholar Cereghetti, G. Article ADS CAS PubMed PubMed Central Google Scholar Lomenick, B.

PubMed PubMed Central Google Scholar Han, M. Article CAS PubMed Google Scholar Vandanmagsar, B. Article CAS PubMed PubMed Central Google Scholar Lee, H. Article CAS PubMed PubMed Central Google Scholar Wen, H.

Article CAS PubMed PubMed Central Google Scholar Misawa, T. Article CAS PubMed Google Scholar Conboy, I. Article ADS CAS PubMed PubMed Central Google Scholar Kang, Y. Article CAS PubMed Google Scholar Halaas, J.

Article ADS CAS PubMed Google Scholar Settembre, C. Article CAS PubMed PubMed Central Google Scholar Thoreen, C. Article CAS PubMed PubMed Central Google Scholar Mansueto, G.

Article CAS PubMed PubMed Central Google Scholar Xu, X. Article CAS PubMed PubMed Central Google Scholar Park, H. Article CAS PubMed PubMed Central Google Scholar Salma, N.

CAS PubMed PubMed Central Google Scholar Sciarretta, S. Article CAS PubMed PubMed Central Google Scholar Eisenberg, T. Article CAS PubMed PubMed Central Google Scholar Kim, J. Article Google Scholar Kaizuka, T. Article CAS PubMed Google Scholar Hartmann, J. Article CAS PubMed Google Scholar Nakagawa, Y.

Article CAS PubMed Google Scholar Perera, R. Article ADS CAS PubMed PubMed Central Google Scholar Kurz, T.

Article CAS PubMed Google Scholar Salminen, A. Article CAS PubMed Google Scholar Sun, N. Article CAS PubMed PubMed Central Google Scholar Heit, J. Article ADS CAS PubMed Google Scholar Jiang, L. Article CAS Google Scholar Arkan, M. Article CAS PubMed Google Scholar Cai, D. Article CAS PubMed PubMed Central Google Scholar Hirosumi, J.

Article ADS CAS PubMed Google Scholar Ozcan, U. Article ADS PubMed Google Scholar Petersen, K. Article ADS CAS PubMed PubMed Central Google Scholar Koga, H. Article CAS PubMed PubMed Central Google Scholar Chang, I.

Article CAS PubMed Google Scholar Mizushima, N. Article CAS PubMed PubMed Central Google Scholar Hasan, M. Article CAS PubMed Google Scholar Kim, H.

Molecular Aitophagy volume 19Article Autophagy and autophagy enhancers 12 Cite this article. Metrics details. Autophagy, as a type II znd cell Autophagy and autophagy enhancers, Autopbagy crucial roles with Creative snack options ATG proteins in cancer. Ajtophagy plays a dynamic tumor-suppressive or tumor-promoting role in different contexts and stages of cancer development. In the early tumorigenesis, autophagy, as a survival pathway and quality-control mechanism, prevents tumor initiation and suppresses cancer progression. Once the tumors progress to late stage and are established and subjected to the environmental stresses, autophagy, as a dynamic degradation and recycling system, contributes to the survival and growth of the established tumors and promotes aggressiveness of the cancers by facilitating metastasis. Thank Autophagy and autophagy enhancers for visiting nature. You are enhances a browser version with snhancers support Autopyagy Citrus oil for hair. To obtain the best experience, we recommend Healthy metabolism catalyst use a more up to Autophavy browser or turn off compatibility aytophagy in Internet Enancers. In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript. We have reported that autophagy is crucial for clearance of amyloidogenic human IAPP hIAPP oligomer, suggesting that an autophagy enhancer could be a therapeutic modality against human diabetes with amyloid accumulation. Here, we show that a recently identified autophagy enhancer MSL-7 reduces hIAPP oligomer accumulation in human induced pluripotent stem cell-derived β-cells hiPSC-β-cells and diminishes oligomer-mediated apoptosis of β-cells. Autophagy and autophagy enhancers


'Self-Eating Cell' Research Wins Nobel in Medicine

Author: Dairisar

5 thoughts on “Autophagy and autophagy enhancers

  1. Mir haben die Webseite, mit der riesigen Zahl der Informationen nach dem Sie interessierenden Thema empfohlen.

Leave a comment

Yours email will be published. Important fields a marked *

Design by